BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32267900)

  • 21. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.
    Stern JL; Theodorescu D; Vogelstein B; Papadopoulos N; Cech TR
    Genes Dev; 2015 Nov; 29(21):2219-24. PubMed ID: 26515115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complex context relationships between DNA methylation and accessibility, histone marks, and hTERT gene expression in acute promyelocytic leukemia cells: perspectives for all-trans retinoic acid in cancer therapy.
    Garsuault D; Bouyer C; Nguyen E; Kandhari R; Prochazkova-Carlotti M; Chevret E; Forgez P; Ségal-Bendirdjian E
    Mol Oncol; 2020 Jun; 14(6):1310-1326. PubMed ID: 32239597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
    Griewank KG; Murali R; Schilling B; Schimming T; Möller I; Moll I; Schwamborn M; Sucker A; Zimmer L; Schadendorf D; Hillen U
    PLoS One; 2013; 8(11):e80354. PubMed ID: 24260374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory Single Nucleotide Polymorphism Increases TERT Promoter Activity in Thyroid Carcinoma Cells.
    Hirokawa T; Arimasu Y; Chiba T; Nakazato Y; Fujiwara M; Kamma H
    Pathobiology; 2020; 87(6):338-344. PubMed ID: 33227798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TERT promoter mutation in adult granulosa cell tumor of the ovary.
    Pilsworth JA; Cochrane DR; Xia Z; Aubert G; Färkkilä AEM; Horlings HM; Yanagida S; Yang W; Lim JLP; Wang YK; Bashashati A; Keul J; Wong A; Norris K; Brucker SY; Taran FA; Krämer B; Staebler A; van Meurs H; Oliva E; Shah SP; Kommoss S; Kommoss F; Gilks CB; Baird DM; Huntsman DG
    Mod Pathol; 2018 Jul; 31(7):1107-1115. PubMed ID: 29449679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers.
    Stern JL; Hibshman G; Hu K; Ferrara SE; Costello JC; Kim W; Tamayo P; Cech TR; Huang FW
    Mol Cancer Res; 2020 Jul; 18(7):1050-1062. PubMed ID: 32276990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
    Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
    Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
    Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
    Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
    Campos MA; Macedo S; Fernandes M; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
    J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypomethylated CpG around the transcription start site enables TERT expression and HPV16 E6 regulates TERT methylation in cervical cancer cells.
    Jiang J; Zhao LJ; Zhao C; Zhang G; Zhao Y; Li JR; Li XP; Wei LH
    Gynecol Oncol; 2012 Mar; 124(3):534-41. PubMed ID: 22108635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
    Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
    Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classifying Melanoma by TERT Promoter Mutational Status.
    Shaughnessy M; Njauw CN; Artomov M; Tsao H
    J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
    Li Y; Cheng HS; Chng WJ; Tergaonkar V
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
    Lade-Keller J; Yuusufi S; Riber-Hansen R; Steiniche T; Stougaard M
    Melanoma Res; 2018 Oct; 28(5):398-409. PubMed ID: 29570169
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
    Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
    [No Abstract]   [Full Text] [Related]  

  • 38. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
    Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
    Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
    Koelsche C; Renner M; Hartmann W; Brandt R; Lehner B; Waldburger N; Alldinger I; Schmitt T; Egerer G; Penzel R; Wardelmann E; Schirmacher P; von Deimling A; Mechtersheimer G
    J Exp Clin Cancer Res; 2014 Apr; 33(1):33. PubMed ID: 24726063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.